Hematologist
CION Cancer Clinics
First, second and third generation TKIs for CML, compared | CION Cancer Clinics
The generation is only the order in which CML tablets were developed, not a ranking. Imatinib came first. Dasatinib, nilotinib and bosutinib often lower BCR-ABL faster. Ponatinib and asciminib are mostly kept for resistant disease. For most people in chronic phase, long-term control looks broadly similar, so the choice rests on your heart, lungs, sugar, side effects and steady access. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does "first, second or third generation" actually mean?
- How do the first and later generations differ?
- What should you watch for on each TKI?
- How does a haematologist pick one generation over another?
- Which words will you hear when generations are discussed?
- What do families often get wrong about newer TKIs?
- What can this comparison not tell you?
- Common questions about TKI generations
The short answer
What does "first, second or third generation" actually mean?
The generation is simply the order in which these CML tablets were developed. It is not a ranking. Every tyrosine kinase inhibitor, or TKI, blocks the same faulty signal made by the BCR-ABL gene, and each one controls chronic phase CML well in most people who take it daily.
The three groups, in plain terms
Imatinib was the first. It has been used for the longest time, so doctors know its long-term effects more fully than any other. Dasatinib, nilotinib and bosutinib came next. They block the faulty signal more strongly and often bring the BCR-ABL level down faster. Ponatinib is called third generation. It was designed to work against changes in the gene that the earlier tablets cannot reach. Asciminib is newer still and attaches to the faulty protein at a different spot, so some doctors place it in a group of its own.
Why a faster fall is not the whole story
A quicker drop in BCR-ABL matters for some goals, such as a later attempt to stop treatment. For most people in chronic phase, though, long-term control on the first tablet and on the later ones looks broadly similar in studies so far. That is why the choice is usually driven by your health, your other illnesses and your side effects, not by which tablet is newest.
This page explains the groups. It cannot tell you which tablet suits you. Only your haematologist, who knows your heart, lungs, sugar and blood report, can weigh that.Side by side
How do the first and later generations differ?
First generation (imatinib)
Second and third generation
Longest track record, over two decades of use
Shorter track record, though still many years for the second group
BCR-ABL usually falls steadily
BCR-ABL often falls faster and deeper in the first year
Side effects are often daily nuisances: cramps, puffy eyes, feeling sick
Fewer daily nuisances for some, but more to watch in the heart, lungs, blood vessels or liver
Low-cost generic versions widely available in India
Generics exist for some, not all; cost varies widely
Does not work against most resistant gene changes
Each covers a different set of changes; only some reach T315I
Tablet by tablet
What should you watch for on each TKI?
Every tablet has its own pattern. Knowing yours helps you spot the change worth mentioning at the next visit.
Imatinib
Usually taken with food. Common complaints are muscle cramps, puffiness around the eyes, feeling sick and tiredness. Many settle over the first months.
Serious heart or lung effects are uncommon.Dasatinib
Fluid can build up around the lungs, which shows up as breathlessness or a new cough. It can also lower platelets and make bruising easier.
May not suit
- People with existing lung disease
Nilotinib
Has to be taken on an empty stomach. It can raise blood sugar and cholesterol, affect the heart rhythm and narrow arteries over time.
May not suit
- People with diabetes or heart disease
Bosutinib
Loose motions are common early on and usually ease. Liver blood tests are checked regularly.
Ponatinib
Strong against resistant disease, including T315I. It raises the risk of clots, blocked arteries and high blood pressure, so it is used with close heart checks.
Asciminib
Works at a different site on the faulty protein. Usually kept for people who have already tried other TKIs. Pancreas and blood tests are watched.
Not sure whether this applies to you?
Ask an oncologistMaking the choice
How does a haematologist pick one generation over another?
The choice starts with you, not the tablet. Your haematologist looks at your other illnesses, the medicines you already take, your risk score at diagnosis and what you hope for from treatment.
Your heart, lungs and sugar
If you have diabetes, heart disease or narrowed arteries, a tablet that strains the blood vessels may not suit you. If you have lung trouble, one that can cause fluid around the lungs may be avoided. Kidney and liver health also count.
Daily life and plans
Some tablets need an empty stomach twice a day. Others are taken with a meal. Plans for pregnancy, or a wish to try stopping treatment later, can tip the choice too.
Cost and steady supply
A tablet you can afford every month, without gaps, does more than a newer one you miss. Ask whether Aarogyasri, PM-JAY, CGHS, ECHS, EHS or your insurer covers it, and check the current rules, since they change.
On your report
Which words will you hear when generations are discussed?
- TKI
- Tyrosine kinase inhibitor. A tablet that switches off the faulty signal driving CML.
- Frontline
- The first TKI you are given after diagnosis.
- Intolerance
- The tablet is working, but its side effects are too hard to live with.
- Resistance
- The BCR-ABL level is not falling as expected, or is rising again, while you are taking the tablet.
- Kinase domain mutation
- A change in the BCR-ABL gene that can stop some TKIs from attaching. A lab test looks for it.
- Molecular response
- How far BCR-ABL has fallen on the blood test that tracks your treatment.
Commonly believed
What do families often get wrong about newer TKIs?
"The newest generation must be the strongest choice."
Newer tablets act more strongly on the faulty signal, but they also carry risks the first one does not. For many people in chronic phase, imatinib gives long, steady control. Newer is a different trade-off, not an upgrade.
"Starting on imatinib means the doctor is cutting corners."
Imatinib is a standard first choice in national and international guidance. It is chosen because it is known so well, not because it is cheap. If BCR-ABL does not fall as planned, there are later options.
"Being moved to another generation means the disease is winning."
Most switches happen because of side effects, not because the leukaemia is spreading. A change is often a sign that your team is watching closely.
"We can change tablets ourselves if one feels harsh."
Never swap, skip or stop a TKI on your own. Gaps can let resistant cells grow. Tell your haematologist first; they can often ease the side effect or plan a safe switch.
Being straight with you
What can this comparison not tell you?
It cannot tell you which tablet will work for you, or how long your control will last. People respond differently to the same medicine, and your own BCR-ABL results are the only real measure.
It is not a guide for accelerated or blast phase
Everything above is about chronic phase CML. If your report says accelerated phase or blast crisis, the plan is different and often more intensive, and a transplant may be discussed.
What to bring to your next visit
Bring every BCR-ABL report in date order, a list of all your medicines, including herbal ones, and a note of any side effect with when it started. Ask three questions: why this tablet for me, what should I watch for, and what happens if the level does not fall.
At CION, CML cases are reviewed by the haematology team with a tumour board, so the tablet choice is not one person's view.Questions we are asked
Common questions about TKI generations
Is a second generation TKI better than imatinib?
It often lowers BCR-ABL faster, but that does not make it right for everyone. Studies so far show broadly similar long-term control in chronic phase. Second generation tablets carry their own heart, lung or sugar risks. Your haematologist weighs speed against those risks for your body.
Why did my doctor start with imatinib?
Imatinib has the longest record of safe use and is a standard first choice in guidelines. It may also suit you if you have diabetes, heart trouble or lung disease. Starting with it does not close any doors. If your results fall short, later generations remain open to you.
Can I ask to start on a newer tablet?
Yes, you can ask, and a good haematologist will explain the reasoning. Share your goals, such as hoping to stop treatment one day or planning a family. The answer depends on your risk score, your other illnesses and whether you can get the tablet every month without a break.
What is special about the third generation?
Ponatinib was built to work against resistant gene changes, including T315I, which blocks the earlier tablets. Because it can raise the risk of clots and blocked arteries, it is usually kept for people whose disease has not responded or who carry that change, with close heart checks.
Is asciminib a fourth generation TKI?
Some people call it that, but it is better described as a different kind. It attaches to another part of the faulty protein. It is mostly used after other TKIs have been tried, and sometimes for T315I. Whether it suits you, and whether you can access it in India, is a question for your haematologist.
Are generic TKIs as good as the original brands?
Approved generics contain the same medicine and are widely used in India. What matters most is a steady supply from a reliable source, so you do not miss doses. If you switch source, tell your haematologist, who may check your BCR-ABL level a little more closely afterwards.
Will I have to change generations at some point?
Many people stay on their first tablet for years. A change is considered if side effects are hard to live with, or if BCR-ABL results do not reach the expected levels. Your haematologist tracks this on regular blood tests and will explain each step before anything changes.
Do the newer tablets have fewer side effects?
Not fewer, just different. Imatinib tends to cause daily nuisances like cramps and puffy eyes. Later generations may cause fewer of those, but can affect the heart, blood vessels, lungs, liver or sugar. Regular checks catch most of these early, so report any new symptom.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Chronic Myeloid Leukemia Treatment (PDQ) - Patient Version
- American Cancer Society — Chronic Myeloid Leukemia (CML)
- Cancer Research UK — Chronic myeloid leukaemia (CML)
- Leukemia & Lymphoma Society — Chronic Myeloid Leukemia
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Switching TKI: Reasons and What ChangesWhat happens when a tablet has to changeT315I Mutation: What It Rules OutThe gene change only some TKIs can reachCML Drug Cost and Generic TKIs in IndiaWhat each tablet may cost and what schemes coverChronic Myeloid Leukaemia (CML)The full CML guide from diagnosis onward
Talk to us
Unsure why you were given a particular TKI?
Share your BCR-ABL reports with us. CION's haematology team will go through the choice with you and explain what your results mean.